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Abstract
Background: Transplantation of mononuclear cells (MNCs) has previously been tested as a method to induce therapeutic
angiogenesis to treat limb ischemia in clinical trials. Non-invasive high resolution imaging is required to track the cells and
evaluate clinical relevance after cell transplantation. The hypothesis that MRI can provide in vivo detection and long-term
observation of MNCs labeled with manganese contrast-agent was investigated in ischemic rat legs.
Methods and Findings: The Mn-labeled MNCs were evaluated using 7-tesla high-field magnetic resonance imaging (MRI).
Intramuscular transplanted Mn-labeled MNCs were visualized with MRI for at least 7 and up to 21 days after transplantation
in the ischemic leg. The distribution of Mn-labeled MNCs was similar to that of
111In-labeled MNCs measured with single-
photon emission computed tomography (SPECT) and DiI-dyed MNCs with fluorescence microscopy. In addition, at 1–2 days
after transplantation the volume of the site injected with intact Mn-labeled MNCs was significantly larger than that injected
with dead MNCs, although the dead Mn-labeled MNCs were also found for approximately 2 weeks in the ischemic legs. The
area covered by CD31-positive cells (as a marker of capillary endothelial cells) in the intact Mn-MNCs implanted site at 43
days was significantly larger than that at a site implanted with dead Mn-MNCs.
Conclusions: The present Mn-enhanced MRI method enabled visualization of the transplanted area with a 150–175 mm in-
plane spatial resolution and allowed the migration of labeled-MNCs to be observed for long periods in the same subject.
After further optimization, MRI-based Mn-enhanced cell-tracking could be a useful technique for evaluation of cell therapy
both in research and clinical applications.
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Introduction
Cell therapy to treat cardiovascular disease has come of age. For
instance, bone marrow-derived mononuclear cells (MNCs) have
been used for therapeutic neovascularization not only in animal
models[1,2,3,4], but also in the clinical setting[5,6]. Peripheral
blood MNCs have also been used to induce therapeutic
neovascularization for critical limb ischemia[7,8] and myocardial
infarction[9,10]. However, methods that can be used to reliably
evaluate therapeutic effects and migration of transplanted MNCs
are not well established. In vivo monitoring of the healing process
after cell transplantation, particularly the fate of transplanted cells,
is required for high-precision optimization in order to improve the
efficacy of such cell therapies. In addition, non-invasive imaging of
transplanted MNCs may contribute to understanding the
mechanism underlying therapeutic effects such as angiogene-
sis[11].
There is a rapidly growing interest in tracking cell movements
both in animals and humans[12,13]. Tracking MNCs with
magnetic resonance imaging (MRI) has been used in living tissues
such as skeletal muscle, heart and brain to visualize both the
regenerative therapeutic effect and the location of migrated cells
with a high spatial resolution[14,15,16]. Iron oxide nanoparticles
can enhance cell visualization because the susceptibility difference
significantly alters T2*, especially in high field MRI[17]. Dextran-
coated iron oxide nanoparticles have been found to have a wide
clinical application for detection of hepatic tumors[18]. On the
other hand, iron oxide particles still have several shortcomings as
cell-labeling agents. First, the iron oxide particles stay inside cells
for long periods[19], become engulfed by cardiac macrophag-
es[20], and do not indicate cell viability. Second, iron oxide
particles often provide negative contrast that is difficult to
distinguish from ‘dark regions’ in the body, such as air cavities,
veins and other regions where there is intrinsic iron deposition
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and methods for cell labeling such as vectors, [21] transfection
reagents[22] and electroporation[23].
Manganese (Mn) is known to be a toxic substance that causes
‘manganism’ through chronic exposure in environments such as
mines[24]. The divalent manganese ion (Mn
2+) is also known to be
essential for living organisms. For this reason, there has been a
recent renewed interest in Mn
2+ as a potentially useful positive
contrast agent for T1 weighted MRI. The kinetics of Mn
2+ in the
cell mimics the kinetics of calcium ions (Ca
2+) in many biological
systems[25,26], as Mn
2+ is known to enter cells through ligand- or
voltage-gated Ca
2+ channels[27]. Recently, Mn
2+ agents have
found application with manganese-enhanced MRI (MEMRI) for
visualization of many biological features, including neuronal
pathways[28] and neuro/cytoarchitecture[29,30].
Previous work has used the fact that Mn
2+ can enter cells via
voltage gated Ca
2+ channels during stimulation in order to
enhance excitable cells in the brain[31,32], and to monitor
changes in inotropic status[33] or ischemic disorders[34] in the
heart. The fact that Mn
2+ can enter properly functioning cells has
led to work aimed at developing Mn
2+ or Mn-dipyridoxyl-
diphosphate (Mn-DPDP) as cell viability indicators for cardiac
applications[35]. Mn
2+ has also been applied to immunocyte
labeling in vitro and the toxicity, immunoreactivity, and relaxivity
for MRI have been tested[36]. All of this work has indicated that
Mn
2+ is a useful contrast agent for cellular imaging.
On the basis of prior in vitro work using manganese chloride
(MnCl2) to label cells for MRI[36], a MEMRI-based technique
has been developed for tracing transplanted-peripheral blood-
derived MNCs in vivo. In the present report, the possibility that
MNCs can be labeled with MnCl2 contrast agent to a level
sufficient to allow in vivo detection and tracking by T1-weighted
MRI was tested in the ischemic legs of rats. Kinetics of the
intramuscularly transplanted MNCs were visualized and evalu-
ated using MEMRI, indium-111 (
111In) oxine single-photon
emission computed tomography (SPECT) and fluorescence
microscopy. In order to evaluate the therapeutic effects of the
MNCs, blood flow was measured in the ischemic leg muscle using
laser Doppler perfusion imaging, MR angiography and immu-
nohistochemical analysis for CD31 (platelet endothelial cell
adhesion molecule).
Materials and Methods
All study was performed under a protocol approved by the
Animal Welfare and Use Committee of the National Institute of
Radiological Sciences (Japan, 07-1067-5) and based on the
Helsinki Declaration. Male Wistar rats (114–284 g, 6 to 16
weeks, n=18, donors = 81, SLC, Japan) were used. For
visualization of transplanted MNCs, 2 experiments (short-term
and long-term observations) were performed using a hindlimb
ischemia model in the rat. For the short-term observation
experiment, 2 groups of rats were used. The control group (n=3)
was administered saline while the other group was given Mn-
labeled MNCs (n=3, MNC donors = 9). For the long-term
observation experiment, 3 groups of rats were administered
different substances: a Mn-labeled MNC group with intact
MNCs transplanted into the left hindlimb and dead MNCs into
the right hindlimb (n=6, MNC donors = 36), an intact
111In-
labeled MNCs transplanted group for SPECT imaging (n=1,
MNC donors = 6), and an intact 1,19-dioctadecyl-3,3,39,39-
tetramethylindocarbocyanine (DiI)-labeled MNCs transplanted
group for fluorescent microscopic imaging (0, 2, 14, 21, and 28
days, n=1 for each, MNC donors = 30).
Mn and DiI labeling for peripheral blood MNCs
Donor rats were euthanized with a lethal dose of a pentobarbital
(150 mg/kg, Dainippon-Sumitomo Pharmaceutical, Osaka, Ja-
pan), after which heparinized whole blood was harvested. MNCs
were subsequently separated using Histopaque 1083 (Sigma-
Aldrich, St. Louis, MO, USA)[7]. Osmotic pressure controlled
MnCl2?4H2O (Sigma-Aldrich) was dissolved in PBS with 5%
serum and prepared at 0.25 mM MnCl2 for the hindlimb ischemia
model[36]. MNCs were mixed with the MnCl2 solutions and
incubated for 60 min at 37uC. For the long-term experiment, a
subgroup of cells was marked with a fluorescent (DiI) dye (Life
Technologies Japan, Tokyo, Japan) at a concentration of 2 mg/
ml[37]. DiI was added to PBS with 5% serum and MnCl2 5 min
before the end of incubation. After incubation, the MnCl2 solution
was removed carefully by washing twice using PBS with 5%
serum. Half of the Mn-labeled MNCs were heated in 90uC water
for the dead Mn-labeled MNCs group. Cell viability was
determined by staining with trypan-blue and manually counting
the living and dead cells using an optical microscope.
Animal models
Rats were initially anesthetized with 4.0% isoflurane (Abbott
Japan, Tokyo, Japan), and then kept anesthetized with 2.0%
isoflurane mixed with a 1:7 O2/room-air gas mixture using a
facemask. Rectal temperature was maintained at approximately
37.5uC by an automatic heating system. The proximal part of the
femoral artery and the distal portion of the saphenous artery were
ligated based on the procedure described in a previous report[38].
The intact Mn-labeled MNCs were injected into the left ischemic
hindlimb (7.8665.40610
6 cells in 100 mL) 6 h after the ischemia.
Dead Mn-labeled MNCs (7.8665.40610
6 cells in 100 mL) or
saline (100 mL) were injected into the right ischemic hindlimb.
Paled skin and decreased skin temperature were observed
bilaterally in the hind legs after arterial occlusion. The ability of
the rats to feed and use their legs was monitored every day up until
the experiments were performed. Abnormal gait was typically
observed for 1 week after treatment in all hindlimb ischemic
models. No symptoms of infection or amputation were seen in the
rats throughout the study.
MRI measurements
In vitro MRI measurements. Mn-labeled MNCs (0, 0.1,
0.25, and 0.5 mM, 60 min incubation, washed twice with
phosphate-buffered saline (PBS)) were put into 0.2-mL tubes
with references consisting of saline, 0.1, 0.25, 0.5 mM MnCl2
solution, and the Mn solution remaining after cell-labeling
(supernatant fluid). The MNCs were imaged after centrifuging
into pellet form. The MRI acquisitions were performed 1 h after
the cell preparation with a 7.0-T, 40-cm bore magnet (JASTEC-
Kobelco, Tokyo, Japan) interfaced to a Bruker console (Bruker
Biospin, Ettlingen, Germany). A 75-mm-diameter birdcage
transmitting/receiving coil (Bruker-Biospin) was used for sample
measurement. The polymerase chain reaction (PCR) tubes were
mounted on a plastic holder having a 464 hole arrangement and
this was placed exactly in the center of the coil. The sample
temperature was maintained at room temperature (,23uC). The
in vitro MRI measurements were performed in the following order:
T1-weighted imaging using a conventional spin echo (SE)
sequence, multi-echo SE imaging for transverse relaxation time
(T2) calculations, and an inversion-pulse prepared RARE (rapid
acquisition with relaxation enhancement) sequence for
longitudinal relaxation time (T1) calculations. T1-weighted
imaging: Two sets of 2-dimensional (2D), multi-slice, T1-
weighted images were obtained using a conventional SE
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(TR) = 400 ms, echo time (TE) = 9.57 ms, matrix size =
2566128 (sagittal) or 2566256 (horizontal), field of view (FOV) =
40620 mm
2 (sagittal) or 40640 mm
2 (horizontal), slice thickness
(ST) = 1.2 mm (sagittal) or 1.0 mm (horizontal), slice gap (GAP)
= 9 mm, and number of acquisitions (NA) = 8. Images were
acquired in the sagittal (4 slices) and horizontal orientations (1
slice). The horizontal slice was adjusted so that the pelleted MNCs
lay within it. The nominal voxel resolution was 15661566
1200 mm
3 (sagittal) or 156615661000 mm
3 (horizontal). Multi-
echo imaging: 2D multi-slice multi-echo imaging was performed
to generate T2 maps using a SE sequence with the following
parameters: TR=4000 ms, number of echoes = 16 with TE =
6.8, 13.6, 20.4, 27.2, 34.0, 40.8, 47.6, 54.4, 61.2, 68.0, 74.8, 81.6,
88.4, 95.2, 102.0, and 108.8 ms, matrix size = 1286128, slice
orientation = horizontal (same slice orientation as T1-weighted
imaging), FOV = 40640 mm
2, ST = 1.0 mm, GAP = 1.5 mm,
and NA = 2. The nominal voxel resolution was 31363136
1000 mm
3 (horizontal) for these images. Inversion recovery
imaging: Inversion pulse prepared 2D single-slice RARE
imaging was performed to generate T1 maps with the following
parameters: TR = 16000 ms, TE = 6.8 ms, inversion time =
35, 50, 100, 200, 400, 800, 1600, 3200, 6400 ms, rare factor = 4,
matrix size = 1286128, and NA = 2. The geometry, slice
orientation, and nominal voxel resolution were the same as for the
horizontal multi-echo MRI.
In vivo MRI measurements. Anesthesia in rats was induced
with 4.0% isoflurane and maintained with 2.0% isoflurane using a
facemask. Rectal temperature was monitored using an optical fiber
sensor and maintained at approximately 37.5uC with a heating
pad. MRI acquisitions were performed with the same magnet and
console as the in vitro measurements. A 75-mm-diameter birdcage
transmitting/receiving coil (Bruker-Biospin) was used. The in vivo
MRI measurements were performed in the following order: T1-
weighted imaging using a conventional SE sequence followed by
multi-echo SE imaging for T2 calculations and MR angiography.
T1-weighted imaging: Three sets of 2D, multi-slice, T1-
weighted images were obtained using a conventional SE
sequence with the following parameters: TR = 350 ms, TE =
9.57 ms, matrix size = 2566256, FOV = 44.8644.8 mm
2 (the
FOV was expanded up to 54.4654.4 mm
2 depending on animal
size), ST = 1.5 mm, GAP = 1.5 mm, and NA = 8. Slice
orientation was axial (8 slices with 0 or 1.5 mm slice offset) and
horizontal (5 slices with 0- or 1.5-mm slice offset). The nominal
voxel resolution was typically 175617561500 mm
3, with the
lowest resolution being 212.56212.561500 mm
3. The total
acquisition time for the 2 orientations was 48 min. Multi-echo
imaging: 2D multi-slice multi-echo imaging was performed to
generate T2 maps using a SE sequence with the following
parameters: TR = 12000 ms, number of echoes = 8 with TE =
10, 20, 30, 40, 50, 60, 70 and 80 ms, matrix size = 2566256, slice
orientation = coronal (same slice orientation as T1-weighted
imaging), FOV = 44.8644.8 mm
2 (FOV was expanded up to
54.4654.4 mm
2 depending on animal size), ST = 1.5 mm, GAP
= 1.5 mm, and NA = 2. The nominal voxel resolution was the
same as for the T1-weighted MRI. The total acquisition time for
the multi-echo imaging was 24 min. MR angiography:3 -
dimensional gradient-echo imaging was performed to generate
angiography using a spoiled gradient echo sequence (FLASH) with
the following parameters: TR = 15 ms, TE = 2.4 ms, FA = 20u,
matrix size = 25661286128, FOV = 51.2625.6625.6 mm
2,
and NA = 4. The nominal voxel resolution was 200 mm in all
directions. The total acquisition time for the angiography was
12.28 min.
Low field MRI measurements. To verify the contrast
mechanism of MEMRI, acquisitions were also performed using
0.2 T MRI for an in vitro (n=1) study. For the in vitro MNC
measurements, 2D, multi-slice T1-weighted images were obtained
using a conventional SE sequence with the following parameters:
TR = 300 ms, TE = 25 ms, matrix size = 2566256 (sagittal) or
2566256 (horizontal), FOV = 2006200 mm
2, ST = 1.2 mm
(sagittal) or 1.0 mm (horizontal), GAP = 9 mm, and NA = 4.
Images were acquired in the sagittal (4 slices) and horizontal
orientations (1 slice).
Indium-111 labeled MNCs for SPECT imaging
To visualize the kinetics of the transplanted MNCs using
SPECT, MNCs were labeled with
111In-oxinate (Nihon-Medi-
physics, Tokyo, Japan) by incubating for 30 min at 37.0uC[39].
The radioactive half-life of the
111In was 2.8 days. After
incubation, the cells were washed in 5% serum PBS and
subjected to 400 G centrifugation for 5 min.
111In-oxinate
labeling efficiency was then evaluated using a well counter. The
cells were equally divided into 2 parts. One half was injected into
the ischemic hindlimb with the other half injected into the
opposite intact limb. The rat underwent in vivo imaging with
SPECT (GCA-9300, Toshiba, Japan) 0, 2, 14, 21, and 28 days
after the injection using the same anesthetic condition as for the
MRI observation.
Laser Doppler perfusion imaging
Rats were initially anesthetized with 4.0% isoflurane, after
which anesthesia was maintained with 2.5% isoflurane combined
with a constant air-flow at a rate of 0.5 L/min. The animals were
also placed on a heating pad to maintain the body temperature.
Hindlimb perfusion was measured with a laser Doppler perfusion
analyzer (Moor Instruments, UK) 21 days after disappearance of
Mn enhancement in the T1-weighted MRI (43614 days after
MNC transplantation).
Fluorescence microscopy and immunohistochemical
study
To investigate revascularisation of the tissue, the rats were
euthanized with a lethal dose of pentobarbital (150 mg/kg,
Dainippon-Sumitomo Pharma), after which the ischemic limbs
were extracted and immediately frozen in liquid nitrogen.
Typically, 20 sections were prepared in 12- mms l i c e sf o re a c h
animal and viewed with an inverted fluorescent microscope
(IX71, Olympus, Tokyo, Japan). In addition, we also used rat
monoclonal CD31 antibody (Serotec, Kidlington, UK) for
sections prepared at days 2 and 43. All sections were carefully
examined and digital photographs were obtained at 4 |,2 0|,
and 100 | magnification at the region of highest fluorescence
intensity. To assess the CD31 positive area, we analyzed a
randomly selected 6 areas (0.136 mm
2) in the transplanted site
and calculated the fraction of the total area that was stained by
CD31.
Data analysis
MR imaging analysis. Image reconstruction and analysis
were performed using ParaVision (Bruker-Biospin) and MRVision
(MRVision, Winchester, MA, USA). Quantitative T1 maps were
calculated from the inversion recovery MRI data with a non-linear
least squares fitting. In addition, quantitative T2 maps were
calculated from the multi-echo data using the same fitting.
Relaxation rates (R1 = 1/T1,R 2 = 1/T2) were calculated
directly from the T1 and T2 maps.
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transplanted Mn-labeled MNCs was manually calculated for
every T1-weighted MRI slice by an independent observer using
the ROI tool of the MRVision software. The observer was
thoroughly educated about the anatomical features of the
injection site. Although the threshold for selecting the boundary
of the affected area was generally set at 2 standard deviations of
the peripheral muscle signal, the observer manually determined
the profile-line when the images were complicated by both
positive and negative signal enhancement. MR angiography was
visualized using a maximum intensity projection (MIP) that was
calculated from the 3D-MRI data with the ParaVision tool. With
reference to the 3D-MIP data, the number of arteries was
manually counted in each of the eight transverse slices of the 2D
angiography data covering the distal hindlimb. The mean
number of arteries was then calculated.
Statistics. All results are expressed as the mean 6 standard
error of the mean. Statistical comparison was performed using
two-way analysis of variance (ANOVA) with the Bonferroni post-
hoc test. The statistical calculations were performed using
commercial analysis software (GraphPad Prism, GraphPad
Software, San Diego, CA, USA). Statistical significance was set
to P,0.05.
Results
Relaxation times and contrast of MnCl2-labeled MNCs
In vitro relaxation rates for the pelleted Mn-labeled MNCs,
MnCl2 solution, and supernatant MnCl2 fluid after labeling are
shown in Fig. 1A. An increase of both R1 and R2 was observed for
the pelleted 0.1 mM Mn-labeled MNCs in comparison with the
un-labeled MNCs (Fig. 1A). It was not possible to calculate the R1
and R2 values for the MNCs with 0.25 mM Mn-labeling and over
because the T2 was too short due to the large susceptibility effect.
The R1s of the MnCl2 solutions were approximately linearly
correlated with the concentration (Fig. 1A). The supernatant fluid
remaining after Mn-labeling of MNCs was also measured to
estimate the amount of Mn discharged from the MNCs. Both R1
and R2 for the supernatant fluid were approximately independent
of the initial Mn labeling concentration (Fig. 1A). The results and
trypan-blue staining (viability 95.462.4%, 0.25 mM MnCl2-
labeled MNCs) suggest that there was limited Mn release from
labeled cells and little cytolysis for 0.1–0.5 mM MnCl2-labeling.
Typical T1-weighted images of pelleted MNCs are presented in
Fig. 1B. In the 7-T T1-weighted MRI, the 0.1 mM MnCl2-labeled
MNCs showed an upper layer of positive signal enhancement. The
0.25 and 0.5 mM MnCl2-labeled MNCs suffered signal loss in
Figure 1. Relaxation times and contrast of Mn-labeled MNCs. (A) R1 and R2 calculated for the in vitro samples are presented. The pelleted
0.1 mM Mn-labeled MNCs showed larger R1 and R2 in comparison to the saline control. It was not possible to calculate the R1 and R2 values for the
MNCs with 0.25 mM Mn-labeling and over (N/A) because the T2 was too short due to the large susceptibility effect. The R1s of the MnCl2 solutions
were approximately linearly correlated with the Mn concentration. The R1 and R2 for the supernatant fluid were approximately independent of the
initial Mn labeling concentration. (B) T1-weighted sagittal images of pelleted MNCs after suspension in 0, 0.1, 0.25, and 0.5 mM Mn solutions. The
pelleted MNCs at 0.1 mM MnCl2-labeling showed partial signal enhancement in the T1-weighted 7 T MRI (arrow). The pelleted MNCs with MnCl2-
labeling over 0.25 mM lost signal in comparison with the unlabeled (0 mM) control due to the very short T2 and the T2* susceptibility effect at 7 T. In
the 0.2 T MRI, the the 0.1, 0.25 and 0.5 mM MnCl2-labeled MNCs showed positive contrast, although there may have been some signal loss at the
base of the 0.5 mM sample.
doi:10.1371/journal.pone.0025487.g001
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other hand, in the 0.2 T T1-weighted image the 0.1 and 0.25 mM
MnCl2-labeled MNCs showed uniform positive signal enhance-
ment, while there may have been some signal loss at the base of
the 0.5 mM sample. These results indicate that the signal loss was
not caused by Mn discharge from the cells or cytolysis, but by the
T2 shortening and T2* susceptibility effects caused by the labeled
MNCs. In preparation for the in vivo experiments, we performed
an in vivo trial with both 0.125 and 0.25 mM MnCl2-labeled
MNCs. As the enhancement due to the 0.125 mM MNCs
disappeared within 1 day of transplantation (data not shown), a
concentration of 0.25 mM MnCl2 was used to label MNCs for the
in vivo experiments.
Short-term in vivo tracking of Mn-labeled MNCs in the
ischemic hindlimb
Figure 2A presents typical MR images immediately after
transplantation of Mn-labeled MNCs. Signal loss was observed
at the transplanted site in T1-weighted (A1) and proton-density
(A2) images. Signal enhancement surrounding the ‘dark’ trans-
planted site was also observed in the same images. Furthermore,
shorter T2 at the MNC injected site and longer T2 at the MNC
injected muscle were observed (A3). Figure 2B and 2C present the
dynamics of Mn-labeled MNCs in comparison with saline (as a
control) from immediately after intramuscular administration to 2
days later. Immediately after the injection, both Mn-labeled cells
and saline provided signal reduction on the T1-weighted MRI
(Fig. 2B). At 24–48 h after the injection, Mn-labeled cells were
clearly detected as a ‘‘double-layered structure’’ that has a dark
core with surrounding positive enhancement. The volume of the
transplanted MNCs was unchanged 1 day after the transplanta-
tion, but the volume of the injected saline sites shrank to zero
within 1 day (Fig. 2C).
Long-term in vivo tracking of Mn-labeled MNCs in the
ischemic hindlimb
Figure 3 demonstrates the long-term dynamics of transplanted
MNCs using MRI for both intact and dead Mn-labeled cells,
SPECT for intact
111In-labeled cells, and fluorescence microscopy
for DiI-labeled cells from 0 to 28 days after the intramuscular
administration. The viability of the MnCl2-labeled intact MNCs
before transplantation was more than 95.462.4% in all experi-
ments (trypan-blue staining). The intact Mn-labeled MNCs were
observable for at least 7 and up to 21 days in the injected muscle.
This result agreed with the changes to the radioactive signal
measured by SPECT using
111In-labeled MNCs. The enhanced
volume (normalized by the volume at day 0) of intact Mn-labeled
MNCs was significantly larger than the enhanced volume of dead
Mn-labeled MNCs for the first 1–2 days, and then both gradually
shrank (Fig. 4, bar graph), although the enhanced volume of the
dead Mn-labeled MNCs tended to shrink earlier than the intact
MNCs. The ratio of intact-to-dead MNC enhanced volume
gradually increased until 21 days after the transplantation (Fig. 4,
line graph). Fluorescent DiI-labeled MNCs were observable for 0–
Figure 2. Typical MR images immediately after transplantation of Mn-labeled MNCs and short-term changes of the signal intensity
in ischemic rat legs. A typical horizontal T1-weighted image (A1), proton density image (A2), and calculated T2 map (A3) are presented for the same
animal immediately after the injection of Mn-labeled MNCs. The images on the right are magnifications of the area inside the white rectangles. Mn-
labeled MNCs (white arrows) were injected into the left leg (right side of the images) and saline (white arrow heads) was injected into the right leg
(left side of the images). (B) Short-term observation of T1-weighted signal enhancement in ischemic rat legs is presented. The upper figures show
horizontal T1-weighted MRI after Mn-labeled MNC injection from 0 to 2 days after the transplantation. The lower figures show T1-weighted MRI after
saline injection in the same animal (contralateral leg). The area enclosed by the white dotted lines is an example of a typical region of interest (ROI).
At both 1 and 2 days after injection, Mn-labeled MNCs were visualized as a ‘‘double-layered structure’’ that has a positive outline and dark core (B,
white arrows). The signal reduction after saline injection soon disappeared (B, white arrow head). (C) Volume change after the MNC injection. The
filled triangles indicate volume change at the Mn-labeled MNC injected site and the filled squares correspond to the saline injected site. * Significant
difference vs. volume of saline injected control, level of significance P,0.05 for two-way ANOVA with Bonferroni post-hoc test (n=3).
doi:10.1371/journal.pone.0025487.g002
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were performed at 14 or 21 days, the fluorescence from DiI was
not detected at those times. A very small volume of DiI-labeled
MNCs was observed at 28 days after the injection.
Chronic evaluation of blood flow recovery after MNC
transplantation
Figure 5A and B show typical angiography in the affected
legs. Recovery of arterial blood flow was observed for both the
intact and dead MNC administered legs at 21 days (Table 1).
There was no significant difference in the number of arteries
between the sites where intact and dead MNCs were
transplanted (Fig. 5A and B, Table 1). The ratio of muscle
p e r f u s i o ni nt h el e f ta n dr i g h tlegs (intact-to-dead MNCs)
measured by laser Doppler 43 days after the transplantation
was 12069% (n = 6) (Fig. 5C). After immunohistochemical
staining for CD31 (as a marker of capillary endothelial cells as
well as neutrophil and macrophages), the area covered by
CD31-positive cells (brown) in the intact Mn-MNCs implanted
site at 43 days was larger than that at 2 days or in the dead Mn-
MNCs implanted site at 43 days (Fig. 6).
Discussion
This is the first report describing the transplantation of Mn-
labeled MNCs to a level sufficient for detection over a period of
several weeks in vivo by MRI. There were 2 major findings in this
study: 1) Mn-labeled MNCs were continuously observed by MRI
for at least 7 and up to 21 days after transplantation in the
ischemic leg. This was similar to the
111In-labeled MNCs
visualized by SPECT. 2) The volume of the site injected with
dead MNCs was significantly smaller than that injected with intact
Mn-labeled MNCs at 1–2 days after the transplantation, although
Figure 3. Long-term in vivo observations after transplantation of Mn-labeled MNCs in ischemic rat legs. T1-weighted images of intact
(1
st row) and dead (2
nd row) Mn-labeled MNCs, SPECT images of intact
111In oxine labeled MNCs (3
rd row), and fluorescence microscopy images of
intact DiI-labeled MNCs (4
th row) are presented. The images were obtained between 0 and 28 days after administration. The intact Mn-labeled MNCs
were typically observed for at least 7 and up to 21 days in the injected muscle (arrows). The dead Mn-labeled MNCs (arrow heads) tended to decrease
in volume earlier than the intact MNCs.
doi:10.1371/journal.pone.0025487.g003
Figure 4. Comparison of the enhanced volume in T1-weighted
MRI due to intact and dead Mn-labeled MNCs. The shaded and
white bars indicate the enhanced volume (normalized by the volume
measured at day 0) of the intact and dead Mn-labeled MNCs,
respectively. The enhanced volume of the intact MNCs shrank slower
than that for the dead MNCs (bar-graph). The ratio of intact-to-dead
MNCs is also superimposed as a line-graph (black circles, right vertical
axis). An intact/dead ratio of ‘‘1’’ means that the enhanced volumes on
the T1-weighted MRI are the same for the Mn-labeled intact and dead
MNCs. The intact/dead ratio tended to increase with time. * Significant
difference (P,0.05) between the enhanced volumes of the intact and
dead MNCs, two-way ANOVA with Bonferroni post-hoc test (n=6). #
Significant difference (P,0.05) vs. intact MNCs (day 1) 1 Significant
difference (P,0.05) vs. dead MNCs (day 0) { Significant difference
(P,0.05) vs. dead MNCs (day 1).
doi:10.1371/journal.pone.0025487.g004
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weeks in the ischemic legs.
Mn has been shown to be an effective cell-labeling agent for
lymphocytes[36], isolated pancreatic beta-cells[40], and hepato-
cytes using Mn(III)-transferrin[41] in vitro and luciferase-transfect-
ed human embryonic stem cells in vivo[42]. Although cell-tracking
using quantitative radioisotope imaging has been attempted[43], it
is difficult to observe signal changes non-invasively over a period of
weeks due to the limited radioactive half-life. In addition, the
spatial resolution of clinical SPECT is not as good as that of MRI.
Therefore, MRI provides a more precise evaluation for human
angiogenic therapy using cell transplantation.
Clinical trials of MNC transplantation therapies have been
reported and some technical improvements noted[9,10]. In order
to develop more effective cell therapies, the location, distribution
and function of these cells must be determined in a non-invasive
manner. MRI tracking of magnetically labeled cells following
transplantation or transfusion may fulfill this require-
ment[14,19,20]. In the present study, it was demonstrated in a
rat model of hindlimb ischemia that Mn-labeled MNCs are useful
for in vivo tracking of the implanted cells with possible therapeutic
benefits to perfusion recovery due to neovascularization (Figs. 5,
6).
The transplanted Mn-labeled MNCs were typically detected as
a ‘‘double-layered structure’’ having a negative core with
surrounding positive enhancement in the T1-weighted and
proton-density MRI immediately after the intramuscular admin-
istration (7-T MRI, Fig. 2A1, A2). Previous trials have indicated
that Mn
2+ at a concentration of 1.0 mM in T-lymphocytes can
provide positive contrast in T1-weighted MRI at 11.7 T[36]. On
the other hand, Mn-labeled B lymphoblastoid cell-lines provided
signal loss in 1.0–2.0 mM MnCl2 suspensions[36]. There are
several differences, such as cell type and cell density between
previous and the present in vitro trials of MnCl2 labeling. Some
heme iron from the red blood cells may have been retained with
the MNCs. In this study, a concentration of 0.25 mM MnCl2 was
selected for the legs so as to allow long-term visualization in vivo.
Even though this concentration may produce a dark core, the
location of the transplanted MNCs is easily recognized. Signal
enhancement (corresponding to longer T2) was observed in the
MNC injected muscle on T2-werighted MRI (Fig. 2A3). The
enhancement indicates that MNC transplantation induced edema
and/or gradual inflammatory responses in the muscle.
The dark core of the ‘‘double-layered structure’’ turned positive
2–3 weeks after transplantation in the leg (Fig. 3). Because the
same structure was also present for the saline treated group in the
acute stage, it is speculated that the dark core evident at 24 h after
administration was predominantly caused by T2* shortening[17]
due to tissue damage from the injection or bleeding (Fig. 2B). In
the chronic stage, the mechanism responsible for the dark zone is
not clear, although migration of endogenic phagocytes and
Figure 5. Chronic evaluation of angiogenesis using MRI angiography and Laser Doppler perfusion imaging. Representative MRI
angiographs (A and B) and laser Doppler perfusion images (C) are presented. The MRI angiographic images were obtained at 0 (A) and 21 (B) days
after muscle ischemia and MNC transplantation. Recovery of arterial blood flow was observed in the hindpaw for both the intact and dead MNC
administered legs at 21 days. The intact MNC transplanted side showed a similar number of arteries to the contralateral side containing dead MNCs.
The laser-Doppler perfusion image was acquired 43 days after the ischemia and transplantation (C). The muscle perfusion measured with laser-
Doppler in the left legs (injected with intact MNCs) was 2069% (n=6) higher than that in the right legs (dead MNCs).
doi:10.1371/journal.pone.0025487.g005
Table 1. Evaluation of MR angiography after transplantation
of manganese-labeled mononuclear cells.
Control
(dead)
(n=6)
Therapy
(intact)
(n=6) P
Number of arteries (Day 0) 6.1060.63 6.4060.87 0.664
Number of arteries (Day 21) 8.5660.91* 9.1960.95* 0.172
Values are mean 6 SE.
Significant difference vs. Day 1 group, level of significance P,0.05.
(*) for paired T test.
doi:10.1371/journal.pone.0025487.t001
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extended and became increasingly blurred over the first 1–2 days,
after which the ‘‘double-layered structure’’ typically became a
simple positive enhancement in the T1-weighted MRI for up to 21
days (Fig. 3). This result demonstrates that intramuscularly-
administered Mn-labeled MNCs contribute to MRI contrast as
positive (T1-weighted) signal enhancement, with the dark core
(sometimes accompanied by inhomogeneous signal enhancement)
at the injected site. It is expected that imaging at lower fields, such
as those typically found in clinical scanners, will provide mainly
positive signal enhancement because the T2* susceptibility effect is
not as strong.
The kinetics and volume change of the intact Mn-labeled
MNCs were similar to that of the
111In-labeled MNCs measured
by SPECT. The experiments with
111In-oxine, which never leaks
from labeled cells, support the hypothesis that signal change in the
T1-weighted MRI is predominantly caused by the distribution and
density of labeled MNCs. The kinetics and presence of each cell
was also verified under a microscope with the fluorescence DiI-
labeled MNCs at 0 and 2 days after administration. Although no
fluorescence signal could be found at 7–21 days, it is speculated
that the number of DiI-labeled MNCs gradually decreased with
time because only a small amount of fluorescent signal was
observed at 28 days after transplantation.
There are some limitations to the accuracy of tracking Mn-
labeled MNCs. First, it was difficult to evaluate the injected
volume exactly for the first day. This was because the saline
treated group also had a small contrast change, meaning that the
injected solvent, small tissue damage and/or bleeding also
contributed to the predominantly dark contrast. This becomes
more important with high field MRI because of large susceptibility
differences. Nevertheless, since the contrast generated by the saline
disappeared at 1 day after the injection, the double-layered signal
enhancement must be caused by the Mn-labeled MNCs beyond
that time (Fig. 2B and 2C).
Second, Mn
2+ may be gradually discharged from labeled MNCs
and transported to other cells such as myocytes and macrophages.
The in vivo kinetics of Mn
2+ may mimic that of Ca
2+ because Mn
2+
has an ionic radius similar to that of Ca
2+ and is handled similarly
in many biological systems[25]. Mn
2+ can accumulate via Ca
2+
channels and be stored in the mitochondria for long periods[25]. It
is also known that the rate of discharge from neuronal cells is very
slow[29]. Therefore, even though Mn
2+ may leak from the MNCs,
the discharge rate is probably limited.
Third, it has been reported that the survival rate of grafted
skeletal-muscle precursor cells steadily decreased to 14.661.1% in
24 h and to 7.960.6% in 72 h[44]. In addition, in vivo optical
bioluminescence imaging has shown the degradation of Mn-
labeled cell viability after transplantation[42]. In other words,
although 95.462.4% of the MnCl2-labeled MNCs (0.25 mM)
were intact before transplantation, most of the implanted cells died
within 24 h and were engulfed by phagocytes. This means that the
enhanced volumes of both intact and dead MNCs after
transplantation include unknown numbers of dead cells (Fig. 4,
bar graph). The present results showed that, although the area
displaying contrast due to the dead MNCs shrank faster than that
of the intact MNCs, the dead Mn-labeled MNCs could still be
observed for 2 weeks (Figs. 3, 4). This non-distinctive result may be
caused by the low survival rate of cells after transplantation. The
different periods of enhancement for the intact and dead cells
(Fig. 3) suggests that time-course analysis of MEMRI can detect
small differences in the survival ratio (8,15%) of transplanted
cells.
Despite these limitations, cell labeling using Mn contrast agents
could be a useful tool for tracing transplanted cells in vivo. Further
improvement in the Mn-labeling method, such as higher survival
rate of transplanted cells and a method to stabilize Mn inside cells,
will allow tracking of cells and viability for evaluation of the
therapeutic effects. Iron oxide nanoparticles have also been used to
track injected cells for long periods after transplantation, even
when only a single cell is labeled[45]. The iron-oxide-labeled cells
remain observable for longer than those labeled with Mn[19,20].
On the other hand, Mn
2+ has been proposed as a cell viability
indicator for cardiac applications because Mn only accumulates in
living cells[35,46]. In addition, (depending on the concentration)
Mn
2+ mainly positively enhances the exact site of the transplanted
cells without image distortion due to susceptibility differences in
T1-weighted MRI. Also, although negative contrast was occasion-
ally observed at 7 T, our results at 0.2 T suggest that mainly
positive enhancement will be detected in the low magnetic fields
used for clinical MRI. This property can be used to detect and
distinguish the target in heterogeneous tissues and hollow organs
Figure 6. Immunohistochemistry for CD31. Both intact and dead Mn-MNC implanted sites were stained with CD31 at 2 and 43 days. Necrotic
myofibers and neutrophilic infiltration induced by hindlimb ischemia were observed in both the intact and dead Mn-MNCs implanted sites at day 2.
The bar graph indicates the fraction of the total area covered by CD31-positive cells (brown) of the intact (shaded) and dead (white) Mn-labeled
transplanted MNCs. The areas coevered by CD31-positive cells in the intact Mn-MNCs implanted site at 43 days was larger than that at 2 days or in the
dead Mn-MNCs implanted site at 43 days.
doi:10.1371/journal.pone.0025487.g006
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as air spaces, vessels and bone. Moreover, the Mn-labeling method
is very simple and can be applied to any cell strain, including non-
phagocytic cells, because it only requires suspension in a MnCl2
solution for 15–60 min.
Many papers have reported the toxicity of Mn in cells[24,47].
As observed by inotropic status, Mn toxicity is expected for
concentrations of more than 1 mM in the myocardium[33,42].
Mn toxicity has also been investigated in human lymphocytes[36]
and luciferase-transfected human embryonic stem cells[42]. No
cytotoxic effect was observed for cells suspended for 60 min in
MnCl2 concentrations under 0.5 mM[36]. Therefore, suspension
of cells in 0.25 mM MnCl2 for 60 min can produce sufficient Mn-
labeling while also avoiding possible cell toxicity. In the present
report, counting cells stained with trypan-blue revealed a viability
of intact MNCs of 95.462.4%. However, the double-layered
structure created by the labeled MNCs (Fig. 1B) suggests that
intracellular Mn concentrations (such as intra-mitochondrial Mn)
may be greater than 0.5–1.0 mM because MNCs have phagocytic
activity. Further investigation of intracellular Mn concentration is
required to allow safer and effective Mn-labeling experiments.
The present study used 0.28 mg of MnCl2 for the labeling
procedure. This suggests a method for Mn-labeling for clinical
applications because digestion of 2.3 mg/d of Mn is recommended
for adult humans[48], and the ‘tolerable daily intake’ of Mn is
4.38 mg/d[49]. Further studies of cell labeling with small doses of
Mn are warranted to prepare for clinical trials.
In conclusion, intramuscular transplanted Mn-labeled MNCs
were observed in both of the ischemic legs of rats for over 3 weeks
using 7-T MRI. Observation of Mn-labeled MNCs was verified by
comparing the MRI findings with SPECT and fluorescence
microscopy. The dynamics of intact Mn-labeled MNCs agreed
well with the SPECT imaging of
111In-labeled MNCs in the
ischemic legs. The present Mn-enhanced method enabled
visualization of the transplanted area with a 150–175 mm in-plane
spatial resolution and allowed the migration of labeled-MNCs to
be observed for long periods in the same animal. Although it still
needs to be investigated whether the Mn-labeling technique can
reflect the cell viability, after further optimization MRI-based Mn-
enhanced cell-tracking could be a useful technique for evaluation
of cell therapy both in research and clinical applications.
Acknowledgments
The authors thank Ms. Sayaka Shibata (National Institute of Radiological
Sciences, Japan; NIRS) and Dr. Shigeyoshi Saito (Osaka University, Japan)
for technical assistance.
Author Contributions
Conceived and designed the experiments: KO IA IK TS. Performed the
experiments: KO JM KT HT TM. Analyzed the data: KO IA JM.
Contributed reagents/materials/analysis tools: KT. Wrote the paper: KO
IA JM JK TM TS. Conceived and designed the experiments (SPECT): TI
TF.
References
1. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, et al. (2001)
Neovascularization of ischemic myocardium by human bone-marrow-derived
angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves
cardiac function. Nat Med 7: 430–436.
2. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, et al. (1999) Bone
marrow origin of endothelial progenitor cells responsible for postnatal
vasculogenesis in physiological and pathological neovascularization. Circ Res
85: 221–228.
3. Ikenaga S, Hamano K, Nishida M, Kobayashi T, Li TS, et al. (2001) Autologous
bone marrow implantation induced angiogenesis and improved deteriorated
exercise capacity in a rat ischemic hindlimb model. J Surg Res 96: 277–283.
4. Shintani S, Murohara T, Ikeda H, Ueno T, Sasaki K, et al. (2001)
Augmentation of postnatal neovascularization with autologous bone marrow
transplantation. Circulation 103: 897–903.
5. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, et al.
(2002) Therapeutic angiogenesis for patients with limb ischaemia by autologous
transplantation of bone-marrow cells: a pilot study and a randomised controlled
trial. Lancet 360: 427–435.
6. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, et al. (2006)
Intracoronary bone marrow-derived progenitor cells in acute myocardial
infarction. N Engl J Med 355: 1210–1221.
7. Tateno K, Minamino T, Toko H, Akazawa H, Shimizu N, et al. (2006) Critical
roles of muscle-secreted angiogenic factors in therapeutic neovascularization.
Circ Res 98: 1194–1202.
8. Moriya J, Minamino T, Tateno K, Shimizu N, Kuwabara Y, et al. (2009) Long-
term outcome of therapeutic neovascularization using peripheral blood
mononuclear cells for limb ischemia. Circ Cardiovasc Interv 2: 245–254.
9. Tatsumi T, Ashihara E, Yasui T, Matsunaga S, Kido A, et al. (2007)
Intracoronary transplantation of non-expanded peripheral blood-derived
mononuclear cells promotes improvement of cardiac function in patients with
acute myocardial infarction. Circ J 71: 1199–1207.
10. Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, et al.
(2006) Transcoronary transplantation of progenitor cells after myocardial
infarction. N Engl J Med 355: 1222–1232.
11. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, et al. (2004)
Bone marrow-derived cells do not incorporate into the adult growing
vasculature. Circ Res 94: 230–238.
12. Bulte JW, Ma LD, Magin RL, Kamman RL, Hulstaert CE, et al. (1993)
Selective MR imaging of labeled human peripheral blood mononuclear cells by
liposome mediated incorporation of dextran-magnetite particles. Magn Reson
Med 29: 32–37.
13. Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, et al. (2001)
Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking
of stem cells. Nat Biotechnol 19: 1141–1147.
14. Kraitchman DL, Heldman AW, Atalar E, Amado LC, Martin BJ, et al. (2003) In
vivo magnetic resonance imaging of mesenchymal stem cells in myocardial
infarction. Circulation 107: 2290–2293.
15. Winkler T, von Roth P, Schuman MR, Sieland K, Stoltenburg-Didinger G,
et al. (2008) In vivo visualization of locally transplanted mesenchymal stem cells
in the severely injured muscle in rats. Tissue Eng Part A 14: 1149–1160.
16. Zelivyanskaya ML, Nelson JA, Poluektova L, Uberti M, Mellon M, et al. (2003)
Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field
magnetic resonance imaging. J Neurosci Res 73: 284–295.
17. Weisskoff RM, Zuo CS, Boxerman JL, Rosen BR (1994) Microscopic
susceptibility variation and transverse relaxation: theory and experiment. Magn
Reson Med 31: 601–610.
18. Hendrick RE, Haacke EM (1993) Basic physics of MR contrast agents and
maximization of image contrast. J Magn Reson Imaging 3: 137–148.
19. Leor J, Rozen L, Zuloff-Shani A, Feinberg MS, Amsalem Y, et al. (2006) Ex vivo
activated human macrophages improve healing, remodeling, and function of the
infarcted heart. Circulation 114: I94–100.
20. Amsalem Y, Mardor Y, Feinberg MS, Landa N, Miller L, et al. (2007) Iron-
oxide labeling and outcome of transplanted mesenchymal stem cells in the
infarcted myocardium. Circulation 116: I38–45.
21. Toyoda K, Tooyama I, Kato M, Sato H, Morikawa S, et al. (2004) Effective
magnetic labeling of transplanted cells with HVJ-E for magnetic resonance
imaging. Neuroreport 15: 589–593.
22. Hoehn M, Kustermann E, Blunk J, Wiedermann D, Trapp T, et al. (2002)
Monitoring of implanted stem cell migration in vivo: a highly resolved in vivo
magnetic resonance imaging investigation of experimental stroke in rat. Proc
Natl Acad Sci U S A 99: 16267–16272.
23. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, et al. (2005) In
vivo tracking of genetically engineered, anti-HER2/neu directed natural killer
cells to HER2/neu positive mammary tumors with magnetic resonance imaging.
Eur Radiol 15: 4–13.
24. Graham DG (1984) Catecholamine toxicity: a proposal for the molecular
pathogenesis of manganese neurotoxicity and Parkinson’s disease. Neurotoxi-
cology 5: 83–95.
25. Hunter DR, Komai H, Haworth RA, Jackson MD, Berkoff HA (1980)
Comparison of Ca2+,S r 2 +, and Mn2+ fluxes in mitochondria of the perfused
rat heart. Circ Res 47: 721–727.
26. Shibuya I, Douglas WW (1992) Calcium channels in rat melanotrophs are
permeable to manganese, cobalt, cadmium, and lanthanum, but not to nickel:
evidence provided by fluorescence changes in fura-2-loaded cells. Endocrinology
131: 1936–1941.
27. Narita K, Kawasaki F, Kita H (1990) Mn and Mg influxes through Ca channels
of motor nerve terminals are prevented by verapamil in frogs. Brain Res 510:
289–295.
Tracking Grafted Mononuclear Cells Using MEMRI
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e2548728. Pautler RG, Silva AC, Koretsky AP (1998) In vivo neuronal tract tracing using
manganese-enhanced magnetic resonance imaging. Magn Reson Med 40:
740–748.
29. Aoki I, Wu YJ, Silva AC, Lynch RM, Koretsky AP (2004) In vivo detection of
neuroarchitecture in the rodent brain using manganese-enhanced MRI.
Neuroimage 22: 1046–1059.
30. Watanabe T, Michaelis T, Frahm J (2001) Mapping of retinal projections in the
living rat using high-resolution 3D gradient-echo MRI with Mn2+-induced
contrast. Magn Reson Med 46: 424–429.
31. Lin YJ, Koretsky AP (1997) Manganese ion enhances T1-weighted MRI during
brain activation: an approach to direct imaging of brain function. Magn Reson
Med 38: 378–388.
32. Aoki I, Tanaka C, Takegami T, Ebisu T, Umeda M, et al. (2002) Dynamic
activity-induced manganese-dependent contrast magnetic resonance imaging
(DAIM MRI). Magn Reson Med 48: 927–933.
33. Hu TC, Pautler RG, MacGowan GA, Koretsky AP (2001) Manganese-
enhanced MRI of mouse heart during changes in inotropy. Magn Reson Med
46: 884–890.
34. Hu TC, Christian TF, Aletras AH, Taylor JL, Koretsky AP, et al. (2005)
Manganese enhanced magnetic resonance imaging of normal and ischemic
canine heart. Magn Reson Med 54: 196–200.
35. Brurok H, Skoglund T, Berg K, Skarra S, Karlsson JO, et al. (1999) Myocardial
manganese elevation and proton relaxivity enhancement with manganese
dipyridoxyl diphosphate. Ex vivo assessments in normally perfused and ischemic
guinea pig hearts. NMR Biomed 12: 364–372.
36. Aoki I, Takahashi Y, Chuang KH, Silva AC, Igarashi T, et al. (2006) Cell
labeling for magnetic resonance imaging with the T1 agent manganese chloride.
NMR Biomed 19: 50–59.
37. Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, et al. (2006) Monocyte
accumulation in mouse atherogenesis is progressive and proportional to extent of
disease. Proc Natl Acad Sci U S A 103: 10340–10345.
38. Tang GL, Chang DS, Sarkar R, Wang R, Messina LM (2005) The effect of
gradual or acute arterial occlusion on skeletal muscle blood flow, arteriogenesis,
and inflammation in rat hindlimb ischemia. J Vasc Surg 41: 312–320.
39. Nowak B, Weber C, Schober A, Zeiffer U, Liehn EA, et al. (2007) Indium-111
oxine labelling affects the cellular integrity of haematopoietic progenitor cells.
Eur J Nucl Med Mol Imaging 34: 715–721.
40. Gimi B, Leoni L, Desai T,, Magin RL, Roman BB. Imaging of pancreatic beta
cell function by Mn
2+-enchanced MRI. In: Proceedings of the 10
th Annual
Meeting of the ISMRM; 18–24 May 2002;. Honolulu, Hawaii. 567 p.
41. Sotak CH, Sharer K, Koretsky AP (2008) Manganese cell labeling of murine
hepatocytes using manganese(III)-transferrin. Contrast Media Mol Imaging 3:
95–105.
42. Yamada M, Gurney PT, Chung J, Kundu P, Drukker M, et al. (2009)
Manganese-guided cellular MRI of human embryonic stem cell and human
bone marrow stromal cell viability. Magn Reson Med 62: 1047–1054.
43. Aicher A, Brenner W, Zuhayra M, Badorff C, Massoudi S, et al. (2003)
Assessment of the tissue distribution of transplanted human endothelial
progenitor cells by radioactive labeling. Circulation 107: 2134–2139.
44. Suzuki K, Murtuza B, Beauchamp JR, Brand NJ, Barton PJ, et al. (2004) Role of
interleukin-1beta in acute inflammation and graft death after cell transplantation
to the heart. Circulation 110: II219–224.
45. Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, et al. (2004) MRI
detection of single particles for cellular imaging. Proc Natl Acad Sci U S A 101:
10901–10906.
46. Hu TC, Bao W, Lenhard SC, Schaeffer TR, Yue TL, et al. (2004) Simultaneous
assessment of left-ventricular infarction size, function and tissue viability in a
murine model of myocardial infarction by cardiac manganese-enhanced
magnetic resonance imaging (MEMRI). NMR Biomed 17: 620–626.
47. Archibald FS, Tyree C (1987) Manganese poisoning and the attack of trivalent
manganese upon catecholamines. Arch Biochem Biophys 256: 638–650.
48. Trumbo P, Yates AA, Schlicker S, Poos M (2001) Dietary reference intakes:
vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron,
manganese, molybdenum, nickel, silicon, vanadium, and zinc. J Am Diet Assoc
101: 294–301.
49. World-Health-Organization (1996) Health criteria and other supporting
information. WHO (1996) Guidelines for drinking-water quality, 2nd ed
Geneva. pp 276–284.
Tracking Grafted Mononuclear Cells Using MEMRI
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e25487